Biosimilar competition is fueled in the domestic pharmaceutical market

Competition among biosimilars will get severe in the domestic pharmaceutical market.

The market, which has been steady since the launch of Celltrion’s Remsima on November 2012, is getting fueled by patent expirations of large products. Brensis, an Enbrel biosimilar, will be launched next month, and a biosimilar of Lantus, a basal insulin, is planning to enter the market early in the next year....